Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could represent a promising development for body loss . Preliminary human tests have indicated impressive reductions in body mass , potentially exceeding other weight-loss medications . However , additional study is required